NCT03285802View on ClinicalTrials.gov

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 7, 2017

Primary Completion Date

February 12, 2019

Study Completion Date

February 12, 2019

Conditions
Uterine Cancer
Interventions
DRUG

Letrozole

Letrozole 2.5mg will be taken daily q 30 days

DRUG

Everolimus

Everolimus 10mg daily q 28 days

Trial Locations (1)

21204

Greater Baltimore Medical Center, Baltimore

All Listed Sponsors
lead

Greater Baltimore Medical Center

OTHER

NCT03285802 - Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation | Biotech Hunter | Biotech Hunter